50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Dolby Laboratories CEO Kevin Yeaman sells shares worth $4.66 million

Published 27/11/2024, 23:48
Dolby Laboratories CEO Kevin Yeaman sells shares worth $4.66 million
DLB
-

Kevin Yeaman, President and CEO of Dolby Laboratories , Inc. (NYSE:DLB), recently executed a series of stock transactions involving the company's Class A common stock. According to a recent SEC filing, Yeaman sold shares totaling approximately $4.66 million. The sales occurred at prices ranging from $80.19 to $81.1764 per share.

On November 25 and 26, Yeaman sold a total of 57,888 shares. Additionally, he exercised stock options, acquiring 57,888 shares at $62.32 per share, which were then sold. These transactions were conducted indirectly by a trust, the Kevin and Rachel Yeaman Family Trust.

As of the latest filing, Yeaman holds 120,320 shares, which include restricted stock units subject to vesting conditions.

In other recent news, Dolby Laboratories posted strong fourth quarter earnings, with adjusted earnings per share (EPS) of $0.81, significantly above the $0.45 consensus estimate. However, the revenue for the quarter was $305 million, slightly lower than the $307.94 million analysts had projected. These recent developments include Rosenblatt Securities raising its price target for Dolby Laboratories from $98 to $100, maintaining a Buy rating based on the company's robust performance and promising outlook.

The company's forward-looking guidance for fiscal year 2025 has exceeded analyst expectations, reflecting a stable demand and benefits from the recent GE Licensing deal. Dolby Laboratories also reported a full fiscal year 2024 revenue of $1.27 billion and an adjusted EPS of $3.79. The firm anticipates its licensing revenue, a significant part of its business, to be between $305 million and $335 million in Q1 2025.

Rosenblatt's endorsement of a Buy rating and the increased price target demonstrate confidence in Dolby Laboratories' strategic direction and market opportunities. The company's focus on innovation, including the growing adoption of its Atmos and Vision technologies, is expected to contribute to its financial growth and market position.

InvestingPro Insights

Dolby Laboratories' financial health and market position offer additional context to CEO Kevin Yeaman's recent stock transactions. According to InvestingPro data, Dolby boasts a market capitalization of $7.47 billion, reflecting its significant presence in the audio technology sector.

The company's financial stability is underscored by an InvestingPro Tip indicating that Dolby "holds more cash than debt on its balance sheet." This strong liquidity position aligns with another tip stating that "liquid assets exceed short term obligations," suggesting a robust financial foundation that may provide reassurance to investors in light of the CEO's stock sales.

Dolby's commitment to shareholder returns is evident in its dividend history. An InvestingPro Tip highlights that the company "has raised its dividend for 11 consecutive years," with a current dividend yield of 1.64%. This consistent dividend growth may be attractive to income-focused investors and could offset concerns about insider selling.

The company's profitability metrics are also noteworthy. With a gross profit margin of 88.97% for the last twelve months as of Q4 2024, Dolby demonstrates "impressive gross profit margins," as noted by another InvestingPro Tip. This high margin reflects the company's strong pricing power and efficient cost management in its core operations.

While the stock's recent performance shows a 10.36% price total return over the past month, it's trading at 86.83% of its 52-week high. This, coupled with the InvestingPro Tip that Dolby is "trading at a low P/E ratio relative to near-term earnings growth," suggests potential value for investors at current levels.

For readers interested in a more comprehensive analysis, InvestingPro offers 10 additional tips for Dolby Laboratories, providing a deeper dive into the company's financial health and market prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.